Reddy, D. Bhaskar; Reddy, D. Bhaskara; Reddy, N. Subba, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1984, vol. 23, # 10, p. 983 - 985
Metal-free visible-light-promoted C(sp<sup>3</sup>)–H functionalization of aliphatic cyclic ethers using trace O<sub>2</sub>
作者:Ben Niu、Bryan G. Blackburn、Krishnakumar Sachidanandan、Maria Victoria Cooke、Sébastien Laulhé
DOI:10.1039/d1gc03482k
日期:——
Presented is a light-promoted C–C bond forming reaction yielding sulfone and phosphate derivatives at room temperature in the absence of metals or photoredox catalyst. This transformation proceeds in neat conditions through an auto-oxidationmechanism which is maintained through the leaching of trace amounts of O2 as sole green oxidant.
In Situ Generation of Unstable Difluoromethylphosphonate-Containing Diazoalkanes and Their Use in [3 + 2] Cycloaddition Reactions with Vinyl Sulfones
作者:Haibo Mei、Li Wang、Romana Pajkert、Qian Wang、Jingcheng Xu、Jiang Liu、Gerd-Volker Röschenthaler、Jianlin Han
DOI:10.1021/acs.orglett.1c00150
日期:2021.2.5
diazoalkanes with vinyl sulfones under simple reaction conditions is developed, which provides an efficient route toward functionalized fluorinated pyrazolines derivatives in good chemical yields. The difluoro diazoalkanes are generated in situ using t-BuONO for the diazotization of (β-amino-α,α-difluoroethyl)phosphonates, and their stabilities and reactivities were carefully investigated.
Prodrugs of proton pump inhibitors background of the invention
申请人:Garst Michael
公开号:US20050143423A1
公开(公告)日:2005-06-30
Prodrugs of proton pump inhibitors of Formulas 1 through 4,
where the symbols are as defined in the specification, and the R group includes at least one acidic group or its pharmaceutically acceptable salt, have improved aqueous solubility and bioavailability.
Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety
申请人:Garst Michael E.
公开号:US20100113524A1
公开(公告)日:2010-05-06
The compounds of the formulas (I), (II), (III) and (IV), where the symbols are as defined in the specification are prodrugs of proton pump inhibitors. The R
4
group includes at least one acidic group or its pharmaceutically acceptable salt, and the compound having the R
4
group have improved aqueous solubility, stability in plasma and improved bioavailability.